Background | Resources | Articles
Global HIV Vaccine Development
Although progress has been made in the global fight against HIV/AIDS, the epidemic continues to devastate the United States and the international community with 56,300 new HIV infections each year in the United States and an estimated 33 million people living with HIV worldwide. As the leading US government institute for HIV/AIDS research, NIAID is committed to conducting the research necessary to successfully end the fight against HIV/AIDS.
Through laboratories and clinics on the National Institutes of Health campus in Bethesda, Maryland, and a vast network of supported research at universities, medical centers and clinical trial sites around the globe, NIAID is working to better understand HIV and how it causes disease, find new tools to prevent HIV infection including a preventive vaccine, develop new and more effective treatments for people infected with HIV, and hopefully, find a cure.
Learn more about NIAID's role in HIV/AIDS research.
More than 33 million people worldwide live with HIV (World Health Organization, 2009). Currently, there is no vaccine available to prevent HIV infection. Antiretroviral therapy can control progression to AIDS but cannot cure or thwart spread of the disease. For every person that begins treatment, about three more become infected. Historically, vaccines have impacted significantly the spread of infectious diseases such as smallpox, polio, measles, and yellow fever. Similarly, HIV vaccines represent the best long-term hope for ending the HIV pandemic.
Back to Top
For Resources and Articles, Log-in as an OSAP Member